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Introduction
Genetic factors are involved in migraine [1], and may
also play a role e.g., in chronic tension-type headache [2].
The catechol-O-methyltransferase (COMT) gene is one of
several potential headache genetic determinants. COMT
is an enzyme that inactivates catecholamines and cate-
chol-containing drugs, and a substitution of valine (Val)
by methionine (Met) at codon 158 affects the activity of
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transferase (COMT) gene contains a
functional polymorphism, Val158Met,
that has been found to influence
human pain perception, and one
study has found that migraine was
less likely among those with the
Val/Val polymorphism. In the
1995–97 Nord-Trøndelag Health
(HUNT) Study, the association
between the Val158Met polymor-
phism and headache was evaluated in
a random sample of 2451 individuals.
No association between Val158Met
polymorphism and migraine was
found. Among women, a lower preva-
lence of non-migrainous headache
was found among individuals with
the Val/Val genotype than among
those with other genotypes (26.2% vs.
33.6%, p=0.04). That non-migrainous
headache was less likely among wo-
men with the Val/Val genotype may
be an incidental finding, but should
be investigated in further studies.
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the COMT enzyme. Individuals with the Val/Val genotype
have a three- to fourfold higher activity of the COMT
enzyme than those with Met/Met genotype [3].
Individuals with the Val/Val genotype have been found to
be less susceptible to pain and to have an enhanced opi-
oid system response to pain compared with those with
other genotypes [4]. In accordance with this result, two
case-control studies have found that migraine and
fibromyalgia were less frequent among those with the
Val/Val genotype [5, 6].
Based on these findings, our hypothesis was that
headache and migraine were less likely among individuals
with the Val/Val genotype compared with those with other
genotypes. In this population-based study performed
among unselected adults we evaluated the relationship




Between August 1995 and June 1997, all inhabitants aged 20
years or older in Nord-Trøndelag county in Norway were invit-
ed to participate in the Nord-Trøndelag Health Survey
(“Helseundersøkelsen i Nord-Trøndelag”=HUNT). In brief, of
92 566 eligible individuals, 64 560 (70%) participated. Two
questionnaires including >200 health-related questions were
administrated to the participants. The first questionnaire (Q1)
was enclosed with the invitation letter and delivered during
attendance at the health examination. The second questionnaire
(Q2) was filled in after the examination and returned by mail.
The population in Nord-Trøndelag County is ethnically homoge-
neous (less than 3% non-Caucasian), making it suitable for epi-
demiological genetic research [7, 8].
Headache diagnosis
The headache questions in Q2 and the prevalence of headache
are published elsewhere [9, 10]. The headache questions were
designed mainly to determine whether or not the person had
headache, determine frequency of headache and diagnose
migraine according to a modified version of the migraine crite-
ria of the Headache Classification Committee of the IHS [11].
Subjects who answered ‘yes’ to the question “Have you suffered
from headache during the last 12 months?” were classified as
headache sufferers. Based on data from the subsequent 12
headache questions, they were classified into two groups of
either migraine or non-migrainous headache. The diagnoses
were mutually exclusive. Persons were classified as migraineurs
if they reported having migraine or fulfilled the following three
criteria: (i) headache attacks lasting 4–72 hours (<4 hours was
accepted for those who reported visual disturbances often
before headache); (ii) headache with at least one of the follow-
ing three characteristics: (a) pulsating quality, (b) unilateral
location, (c) aggravation by physical activity; (iii) during
headache, at least one of the following symptoms: (a) nausea
and (b) photophobia and/or phonophobia. A headache that did
not fulfil the criteria for migraine was classified as a non-
migrainous headache. Based on a question about headache fre-
quency during the last year, this variable was divided in three
categories; less than 7 days/month, 7–14 days/month and more
than 14 days/month.
The classification of the subjects has been described in
detail previously, and has been validated by interview diagnoses
[9]. In short, for migraine, the positive predictive value (PPV)
was 84% and the negative predictive value (NPV) was 78%; for
non-migrainous headache, the PPV was 68% and the NPV was
76% [9].
Genotyping of the COMT locus
Blood sampling was done whenever subjects attended, and
details for the procedure and the HUNT biobank are described
elsewhere [12].
DNA for genotyping was extracted from peripheral blood
leukocytes from whole blood or blood clots stored in the
HUNT biobank, using the Puregene kit (Gentra Systems Inc.)
manually or with an Autopure LS (Gentra Systems Inc.).
Laboratory technicians were blinded to the headache status of
the samples. COMT genotypes were determined using the
LightCycler (Roche Diagnostics Scandinavia AB, Bromma,
Sweden) fluorescence resonance energy transfer method [10].
Polymerase chain reaction (PCR) amplifications were per-
formed in 20-µl reactions on a LightCycler System, using 2 µl
genomic DNA and the LightCycler-FastStart DNA Master
Hybridization Probes kit (Roche Diagnostics Scandinavia AB,
Bromma, Sweden). PCR primers (Eurogentec, Seraing,
Belgium) and fluorescence labelled probes (PROLIGO, Paris,
France) are shown in Table 1. Based on melting curve profiles,
participants were classified as having Val/Val, Val/Met or
Met/Met genotypes. Details on PCR and melting curve condi-
tions are available on request.








Anchor 5’ LC Red 640-ATCCGCTGGGTGATGGCG-3’
Fl, fluorescein; LC Red 640, LightCycler Red 640
Underlined C indicates polymorphic site
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Participation
Out of the 92 566 invited individuals, a total of 51 383 subjects
(56%) completed the headache questionnaire in Q2. Details of
the non-participants are described elsewhere [7, 10].
In the HUNT biobank a total of 62 664 DNA samples are
stored. At the time of the 1995–1997 HUNT study, participants
were not sufficiently informed about possible genetic DNA-
based research. Therefore, an extensive information campaign
about functional genomic research was performed in 2002, and
each surviving adult HUNT participant (n=61426) received an
information folder and a personal letter asking for re-consent to
include genetic research. In total, 1185 (1.9%) persons with-
drew their consent [7, 8]. Out of the remaining group of 60 241
participants, COMT gene polymorphism analyses were per-
formed on 3048 individuals. Out of the 3048 individuals, a
total of 2451 (80%) subjects also had responded to the
headache questions and were subjects for the present study.
Out of the 3048 individuals with known COMT genotype,
approximately 70% of these were selected completely at ran-
dom. The remaining 30% had been randomly selected among an
older group of individuals. This latter group was generated in
connection with a planned genetic study on diabetes that needed
age-matched controls to a diabetic population. Because diabetes
patients as a group are older than the general population, some-
what older individuals were needed as controls. As a conse-
quence, the total group of 3048 individuals was somewhat older
than the HUNT population as a whole.
Ethics
The study was approved by the Regional Committee for Ethics
in Medical Research, and by the Norwegian Data Inspectorate.
Statistical analysis
Differences between continuous variables were tested with
analyses of variance (one-way ANOVA) and between dichoto-
mous variables with the χ2 test. Analyses used two-tailed esti-
mation of significance, and p<0.05 was considered to be sta-
tistically significant. Overall, our sample of 982 headache suf-
ferers and 1469 controls had the power to detect a 5% differ-
ence in headache prevalence between genotypes with 95% cer-
tainty and 80% power. The sample of 305 migraine patients
and 1469 controls had the power to detect a 3% difference in
migraine prevalence between genotypes with 95% certainty
and 80% power.
Statistical analyses were performed using the Statistical
Package for the Social Sciences (SPSS), version 13.0 (SPSS Inc,
Chicago).
Results
The distribution of genotypes among the 2451 individu-
als was in Hardy-Weinberg equilibrium. Out of these, a
total of 982 persons (346 men and 636 women) with a
mean age of 46.8 years suffered from headache, and the
remaining 1468 individuals with a mean age of 55.5
years were headache-free controls. Among the 982
headache sufferers, 305 (93 men and 212 women) had
migraine and 677 (253 men and 424 women) non-
migrainous headache.
The demographic data according to COMT genotypes
are shown in Table 2. No difference in distribution of gen-
der, mean age or education level was found between the
genotype groups. However, the individuals with known
COMT genotype were significantly older than those with-
out COMT data available (p<0.01) (Table 2).
Comparison of allele distribution of COMT
Val158Met polymorphism by gender failed to detect sig-
nificant differences between headache sufferers and
controls (Table 3). Similarly, the distribution of the
COMT Val158Met genotypes was similar between con-
trols and headache (all types) and migraine. When the
Met/Met and Val/Met genotypes were pooled, headache
was slightly less likely among women with the Val/Val
genotype (44.0%) than in women with other genotypes
(49.3%) (p=0.13). This tendency was explained by a
lower prevalence of non-migrainous headache among
women with the Val/Val genotype than among those
with Val/Met or Met/Met genotypes (26.2% vs. 33.6%,
p=0.04).
Table 2 Distribution of sex, age and education related to COMT genotypes
Characteristics No COMT genotyping Met/Met Met/Val Val/Val
(n=48 932) (n=775) (n=1226) (n=450)
Sex, female (%) 54.0 51.7 54.5 55.1
Age, mean (SD) 48.7 (16.9) 51.9 (18.0) 52.2 (17.7) 51.5 (17.7)
Years of education
<9 (%) 35 36 39 35
10–12 (%) 44 43 42 44
>12 (%) 21 21 19 21
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Discussion
In this population-based study among 2451 unselected
adults, no significant association between migraine and the
Val158Met polymorphism at the COMT gene was found.
Previously, individuals with the COMT Val/Val geno-
type have been found to be less susceptible to pain [4],
and in one study migraine was less frequent among those
with the Val/Val genotype [5]. In contrast, the distribution
of the Val/Val genotype and other genotypes were similar
between controls and migraine patients in the present
study. In accordance with our results, no association was
found between migraine with aura and COMT gene poly-
morphism in a case-control study of 97 patients with
migraine with aura and 94 healthy controls [13].
Similarly, no relationship to the Val158Met polymorphism
at the COMT gene was found in another case-control
study of 103 patients with chronic daily headache with
drug abuse, 101 patients with episodic migraine without
aura and without analgesic abuse, and 117 controls with-
out headache [14]. These conflicting results underline the
importance of testing positive findings by replication in
other populations, because there is a relatively high risk of
positive findings due to coincidence [15].
Of course, non-replications raise concerns about power.
However, our sample of 305 migraine patients and 1469
controls should have 80% power to detect a difference in
migraine prevalence of 3% between genotypes. A limita-
tion of our study is the use of a simplified headache classi-
fication, because headache sufferers were classified into
two groups of either migraine or non-migrainous
headache. Based on our validation study, we have reason to
believe that the majority of individuals with non-migrain-
ous headache suffered from tension-type headache [9].
The observation that COMT activity is lower in
females than in males and that COMT activity may be
under hormonal control [16, 17] is the reason for per-
forming separate analyses for each gender. The prevalence
of non-migrainous headache tended to be lower among
women with the Val/Val genotype than among those with
the other genotypes. This may be an incidental finding,
but should be investigated in further studies including
patients fulfilling the diagnosis of tension-type headache.
If the findings could be replicated, the gender-specific
finding is of interest in light of the well established gen-
der difference in prevalence of headache, and lower pain
threshold in women [18].
Our study could not confirm a strong association
between headache and the Val158Met polymorphism. To
date, no other functional polymorphisms within the
COMT gene have been linked to headache. However, two
other different genetic haplotypes of the COMT gene have
been found to be involved in pain perception in a recent
case-control study [19], and these may be relevant for
headache prevalence.
In conclusion, in this population-based study per-
formed among 2451 unselected adults, no significant
Table 3 Headache prevalence related to genotype of COMT in men and women
Men Women
Met/Met Met/Val Val/Val Met/Met Met/Val Val/Val
No. % No. % No. % No. % No. % No. %
Genotypes
Controls 269 34.1 381 48.4 138 17.5 212 31.1 330 48.5 139 20.4
Headache 105 30.3 177 51.2 64 18.5 189 29.7 338 53.1 109 17.1
Migraine 27 29.0 51 54.8 15 16.1 62 29.2 166 50.0 44 20.8
Non-migrainous 78 30.8 126 49.8 49 19.4 127 30.0 232 54.7 65 15.3
headache
Headache >14 9 33.3 15 55.6 3 11.1 6 19.4 21 67.7 4 12.9
days/month
Alleles Met Val Met Val
Controls 919 58.3 657 41.7 754 55.4 608 44.6
Headache 387 55.2 305 44.1 716 56.3 556 43.7
Migraine 105 56.5 81 43.5 230 54.2 194 45.8
Non-migrainous  282 55.7 224 44.3 486 54.1 412 45.9
headache
Headache >14 33 61.1 21 38.8 33 53.2 29 46.8
days/month
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association between migraine and the Val158Met poly-
morphism at the COMT gene was found. Among women,
non-migrainous headache tended to be less likely among
with those with the Val/Val genotype than among those
with the other genotypes.
Acknowledgements The Nord-Trøndelag Health Study (the
HUNT study) is a collaboration between the HUNT Research
Centre, Faculty of Medicine, The Norwegian University of
Science and Technology (NTNU); Norwegian Institute of Public
Health; and the Nord-Trøndelag County Council
References
1. Ferrari MD, Russell MB (2000)
Genetics of migraine. In: Olesen J,
Tfelt-Hansen P, Welch KMA (eds) The
headaches, 2nd edn. Lippincott
Williams & Wilkins, Philadelphia, pp
241–254
2. Russell MB, Olesen J (2000) Genetics
of tension-type headache. In: Olesen J,
Tfelt-Hansen P, Welch KMA (eds) The
headaches, 2nd edn. Lippincott
Williams & Wilkins, Philadelphia, pp
561–563
3. Lotta T, Vidgren J, Tilgmann C,
Ulmanen I, Melén K, Julkunen I,
Taskinen J (1995) Kinetics of human
soluble and membrane-bound catechol
O-methyltransferase: a revised mecha-
nism and description of the thermola-
bile variant of the enzyme.
Biochemistry 34:4202–4210
4. Zubieta JK, Heitzeg MM, Smith YR et
al (2003) COMT val158  met
Genotype affects µ-opioid neurotrans-
mitter responses to a pain stressor.
Science 299:1240–1243
5. Erdal ME, Herken H, Yilmaz M,
Bayazit YA (2001) Significance of the
catechol-O-methyltransferase gene
polymorphism in migraine. Mol Brain
Res 94:193–196
6. Gürsoy S, Erdal E, Herken H, Madenci
E, Alasehirli, Erdal N (2003)
Significance of the catechol-O-methyl-
transferase gene polymorphism in
fibromyalgia syndrome. Rheumatol Int
23:104–107
7. Holmen J, Midthjell K, Krüger Ø,
Langhammer A, Holmen TL, Bratberg
GH, Vatten L, Lund-Larsen PG (2003)
The Nord-Trøndelag Health Study
1995-97 (HUNT 2): objectives, con-
tents, methods and participation. Nor J
Epidemiol 13:19–32
8. Holmen J, Kjelsaas MB, Krüger Ø,
Ellekjær H, Ross GB, Holmen TL,
Midthjell K, Stavnås PA, Krokstad S
(2004) [Attitudes to genetic epidemiol-
ogy – illustrated by question for re-
consent to 61,426 participants at
HUNT]. Nor J Epidemiol 14:27–31
9. Hagen K, Zwart JA, Vatten L, Stovner
LJ, Bovim G (2000) Head-HUNT:
validity and reliability of a headache
questionnaire in a large population-
based study in Norway. Cephalalgia
20:244–251
10. Hagen K, Zwart JA, Vatten L, Stovner
LJ, Bovim G (2000) Prevalence of
migraine and non-migrainous headache
– Head-HUNT, a large population-
based study. Cephalalgia 20:900–906
11. Headache Classification Committee of
the International Headache Society
(1988) Classification and diagnostic
criteria for headache disorders, cranial
neuralgias, and facial pain. Cephalalgia
8[Suppl 7]:19–28
12. Wittwer CT, Ririe KM, Andrew RV,
David DA, Gundry RA, Balis UJ
(1997) The LightCycler: a microvol-
ume multisample fluorimeter with
rapid temperature control.
Biotechniques 22:176–181
13. Park JW, Kim YJ, Lee KS (2005)
Catechol-O-methyltransferase gene
polymorphism of migraine without
aura. Cephalalgia 25:867
14. Montagna P, Cevoli S, Marzocchi N,
Pierangeli G, Pini LA, Cortelli P,
Mochi M (2003) The genetics of
chronic headaches. Neurol Sci
24[Suppl 2]:S51–S56
15. Sterne JA, Smith GD (2001) Sifting the
evidence – what’s wrong with signifi-
cance tests? BMJ 322:226–231
16. Xie T, Ho SL, Ramsden D (1999)
Characterization and implications of
estrogenic down-regulation of human
catechol-O-methyltransferase gene
transcription. Mol Pharmacol 56:31–38
17. Jiang H, Xie T, Ramsden D, Ho SL
(2003) Human catechol-O-methyltrans-
ferase down-regulation by estradiol.
Neuropharmacology 45:1011–1018
18. Jensen R, Rasmussen BK, Pedersen B,
Lous I, Olesen J (1992) Cephalic mus-
cle tenderness and pressure pain thresh-
old in a general population. Pain
48:197–203
19. Diatchenko L, Slade GD, Nackley AG,
Bhalang K, Sigurdsson A, Belfer I et al
(2005) Genetic basis for individual
variations in pain perception and the
development of a chronic pain condi-
tion. Hum Mol Gen 14:135–143
